Skip to main content
All lobbying filings

THE NICKLES GROUP, LLC

Lobbying for UCB, INC. · Biopharmaceutical company

 Filing 1st Quarter - Report
1st Quarter (Jan 1 - Mar 31) 2025 · Georgia · House · Senate · $60,000.00 income · posted Apr 21, 2025

Official filing document

 Bills named in this filing 5
 Lobbying activity 4
Medicare/Medicaid

Monitored the implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. H.R. 946, ORPHAN Cures Act. Issues related to access to home infusion. Issues related to pharmacy benefit management reforms.

Taxation/Internal Revenue Code

H.R. 1990, the American Innovation and R&D Competitiveness Act, as it relates to the R&D tax credit. Monitored H.R. 591, Defending American Jobs & Investment Act and H.R. 2423, Unfair Tax Prevention Act, as they relate to taxation of foreign-based multinationals. Issues related to the 2025 extension of the Tax Cut and Jobs Act provisions impacting corporations and the Orphan Drug Tax Credit.

Health Issues

Issues related to medication step therapy. S.864, HELP Copays Act, as it relates to out-of-pocket costs for prescription drugs. Issues related to pharmacy benefit management reforms.

Trade (domestic/foreign)

Issues related to tariffs.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem